Sunday, March 09, 2025 3:53:22 PM
J-To,
“One crumb of evidence” might be found among the contract references on page 28 of the recent SEC filing.
Although details are not publicly available yet, we might speculate that “deals” including research collaborations could have been inked with Oncovir, AIM ImmunoTech, and/or any of the companies that make PD-1 drugs. This is a reasonable evidence-based possibility because NWBO’s DC platforms are currently in PII combo trials with pembrolizumab and Ampligen®, and the Hiltonol combo study has concluded and was peer-reviewed.
Another “crumb” can be found around timestamp -1:03 of the ASM recording linked below:
“We have been quietly in-licensing quite a number of different pieces of technology… We also have been putting some collaborations in place …we have not announced those yet…”
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm
https://www.nature.com/articles/s41467-024-48073-y
“One crumb of evidence” might be found among the contract references on page 28 of the recent SEC filing.
Although details are not publicly available yet, we might speculate that “deals” including research collaborations could have been inked with Oncovir, AIM ImmunoTech, and/or any of the companies that make PD-1 drugs. This is a reasonable evidence-based possibility because NWBO’s DC platforms are currently in PII combo trials with pembrolizumab and Ampligen®, and the Hiltonol combo study has concluded and was peer-reviewed.
Another “crumb” can be found around timestamp -1:03 of the ASM recording linked below:
“We have been quietly in-licensing quite a number of different pieces of technology… We also have been putting some collaborations in place …we have not announced those yet…”
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm
https://www.nature.com/articles/s41467-024-48073-y
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
